NCT02840058

Interest of Anti-telomerase T CD4 Immune Responses for Predicting the Effectiveness of Immunotherapies Targeting PD1 / PDL1

• Status: Completed
• Phase: N/A
• Study type: Interventional
• Enrollment: 295 (actual)
• Sponsor: Centre Hospitalier Universitaire de Besancon · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

Recent scientific advances have shown the important role of immune system against cancer. Today, many immunological biotherapy like anti-PD1/PDL-1 are available in cancer treatment and generate durable clinical responses in some patients. The development of tools for monitoring anti-tumor immune responses dynamically is a major challenge to predict the effectiveness of immunotherapies anti-PD-1 and anti-PDL-1. Thus, the objective of our study is to analyse the interest of the monitoring of anti-telomerase T helper 1 (TH1) responses in predicting the efficacy of immunotherapy, using an immunoassay developed by our group.

Conditions

• Cancer

Interventions

Type	Name	Description
OTHER	Biological samples	blood and tumor tissue samples
DRUG	Anti PD1/PDL1 treatment

Timeline

• Start date: 2016-08-31
• Primary completion: 2024-07-23
• Completion: 2025-07-15
• First posted: 2016-07-21
• Last updated: 2026-03-06

Locations

4 sites across 1 country: France